AZ completes US licensing agreement with Ironwood

RNS Number : 1004A
AstraZeneca PLC
03 June 2016
 

ASTRAZENECA COMPLETES US LICENSING AGREEMENT WITH IRONWOOD PHARMACEUTICALS FOR LESINURAD

 

AstraZeneca today announced that it has completed the licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic (lesinurad) and the fixed-dose combination of lesinurad and allopurinol. Zurampic is approved in the US, in combination with a xanthine oxidase inhibitor, for the treatment of hyperuricemia associated with uncontrolled gout. The fixed-dose combination will be submitted for regulatory review in the second half of 2016.

 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

 

 

CONTACTS

 

Media Enquiries

 

 

 


Neil Burrows

UK/Global

+44 7824 350541

Vanessa Rhodes

 

UK/Global

+44 7880 400690

Karen Birmingham

UK/Global

+44 7818 524012

Jacob Lund

 

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

Investor Enquiries



UK



Thomas Kudsk Larsen

 


+44 7818 524185

Nick Stone

RIA

+44 7717 618834

Henry Wheeler

Oncology

+44 7788 354619

 

Craig Marks

Finance

 

+44 7881 615764

Christer Gruvris

ING

+44 7827 836825

US



Lindsey Trickett

  CVMD

+1 240 543 7970

Mitchell Chan

  Oncology

+1 240 477 3771

Dial / Toll-Free


+1 866 381 7277

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal

 

3 June 2016

 

-ENDS-


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRLLFETRVIFIIR

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings